Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC? (BMIC-017)
Автор: BeaconMedIC
Загружено: 2017-12-01
Просмотров: 3156
Описание:
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. "saving" it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC.
Visit http://BeaconMedIC.com for more media & information.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: